Tempus AI, Inc. - Class A Common Stock (TEM)

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of olivia. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQTEM),NYSE:MDTNYSEMDT)(NYSE:TDOCNYSETDOC,(NASDAQ:TALKNASDAQ) EQNX::TICKER_END

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved test that delivers comprehensive insights with one of the largest reported gene panels available.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled services that leverage generative AI to propel privacy-enabled, data-driven decision support in the clinic while simultaneously advancing research to bring new drugs to market. This latest iteration now applies Tempus’ proprietary Large Language Model (LLM) Agent Infrastructure (Agent Builder), which adapts LLMs to work on unstructured, multimodal healthcare data to improve clinical care and research.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test, xH. This test marks Tempus’ first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with detection of all clinically-relevant variants and advancing the landscape of personalized therapy, specifically in hematological oncology.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the 43rd Annual J.P. Morgan Healthcare on January 13-16, 2025, in San Francisco, CA.

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NASDAQ:CRDFNASDAQCRDF)(NASDAQ:PSNLNASDAQPSNL,(NASDAQ:TEMNASDAQ),(NASDAQ:CKPTCKPT) EQNX::TICKER_END

Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions, a laboratory benefit manager. As part of the agreement with Avalon, Tempus is a participating provider with BCBS North Carolina, BCBS South Carolina, BCBS Vermont, Capital BlueCross and CareSource in four markets. This enhances our work with commercial health plans in the East.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQTEM),NYSE:MDTNYSEMDT)(NYSE:SYKNYSESYK,(NASDAQ:PEGANASDAQ) EQNX::TICKER_END

PALM BEACH, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - With the advent of Artificial Intelligence (AI), the methods and techniques to diagnose have helped doctors and patients to understand these diseases in a much faster way, leading to the steady employment of AI in multiple diagnoses around the healthcare industry. The field of medical diagnostics is getting revolutionized due to AI. Medical imaging data, including X-rays, MRIs, and ultrasounds are getting analyzed by AI algorithms to help doctors discover and diagnose diseases more accurately and at a much faster rate. This can assist healthcare professionals in making better judgments regarding patient care, leading to increasing AI in diagnostics market size.   A report from Fact.MR projected that revenue from the global Artificial Intelligence in diagnostics market is projected to reach US$ 1.85 billion in 2024 and thereafter increase swiftly at a CAGR of 23.1% to end up at US$ 14.76 billion by 2034.   The report said: “Health issues are rising among people as the world goes through climate change and other environmental factors, people are getting concerned about their health thus leading to more people going to doctors for diagnosis and proper health checkups.   Medical diagnostics is a process through which doctors understand the condition of a patient's body and analyze whether the patient is suffering from any particular harmful disease. The analysis and results of these tests help doctors use the most suitable course of treatment for their patients to fight the diseases, contributing to the overall expansion of the AI in diagnostics market growth.”   Active companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQTEM), Medtronic plc NYSE: MDTNYSEMDT)(NYSE: SYKNYSESYK, Pegasystems Inc. (NASDAQ: PEGANASDAQ).

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by the Centers for Medicare and Medicaid Services (CMS) that will allow reimbursement for assessments of cardiac dysfunction using the Tempus ECG-AF algorithm. ECG-AF is one of just a few FDA-authorized medical technologies in the country to be impacted by the new CMS decision, and this milestone allows Tempus to more broadly support clinicians in identifying patients at increased risk of atrial fibrillation/flutter (AF).

Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis’ ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors.

EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQRXRX),NASDAQ:TEMNASDAQTEM)(NASDAQ:ISRGNASDAQISRG EQNX::TICKER_END

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, held in New York, New York.

EQNX::TICKER_START (OTCQB:AVAI),(NYSETDOC),NASDAQ:TEMNASDAQTEM)(NYSE:MDTNYSEMDT,(NASDAQ:CLOVNASDAQ) EQNX::TICKER_END

EQNX::TICKER_START (OTCQB:AVAI),(NYSEBFLY),NASDAQ:TEMNASDAQTEM)(NASDAQ:GEHCNASDAQGEHC,(NASDAQ:RDNTNASDAQ) EQNX::TICKER_END

PALM BEACH, Fla. , Nov. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The Healthcare Artificial Intelligence (AI) market exhibits a high degree of innovation, characterized by ongoing advancements in technology. Rapid developments in ML, deep learning, NLP, and computer vision are driving the evolution of AI-powered healthcare solutions. One primary factor driving market growth is the increasing demand in the healthcare sector for enhanced efficiency, accuracy, and better patient outcomes. According to a March 2024 Microsoft-IDC study, 79% of healthcare organizations are presently utilizing AI technology. In addition, the return on investment (ROI) is realized within 14 months, generating USD 3.20 for every USD 1 invested in artificial intelligence (AI). AI technologies hold transformative potential in various areas including medical imaging analysis, predictive analytics, personalized treatment planning, and drug discovery, potentially transforming conventional healthcare practices. A report from Grand View Research said the global AI in healthcare market size, which was estimated at USD 19.27 billion in 2023, is expected to grow at a CAGR of 38.5% from 2024 to 2030. The report said: “Mergers & acquisitions (M&As) play a significant role in shaping the healthcare AI market landscape. Companies [that] engage in M&A activities to expand their AI software and services increase their market reach or acquire specialized technology and expertise. End-users are becoming increasingly aware of the potential benefits of AI in improving patient care, operational efficiency, and healthcare outcomes. Education initiatives and industry events helped raise awareness about the capabilities and applications of AI in healthcare.” A.I. companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Teladoc Health, Inc. (NYSETDOC), Tempus AI, Inc. NASDAQ: TEMNASDAQTEM)(NYSE: MDTNYSEMDT, Clover Health Investments, Corp. (NASDAQ: CLOVNASDAQ).

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly into Flatiron’s cloud-based Electronic Medical Record (EMR) platform, OncoEMR® through the Molecular Profiling Integration (MPI). This integration will provide oncologists with seamless access to Tempus’ suite of testing options, enhancing their ability to deliver personalized cancer care.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, which convenes in Houston, Texas, from November 6-10, 2024.

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a prognostic indicator for adult patients with stage IV and metastatic pan-solid tumors who are already considered candidates for immune checkpoint inhibitor (ICI)-based therapy. Tempus is presenting the results of its validation study at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, which demonstrated that IPS-High patients in the study were more likely to have an overall survival benefit while receiving ICI-based therapy than IPS-Low patients in the study (HR 0.45).

Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended September 30, 2024. The company also announced that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.

Tempus AI, Inc. (NASDAQTEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled.